Stock RGNX REGENXBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials REGENXBIO Inc.

Equities

RGNX

US75901B1070

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
16.19 USD +0.81% Intraday chart for REGENXBIO Inc. +3.19% -9.81%
03-28 REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD CI
03-18 Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,511 1,697 1,399 981.9 789.7 794 - -
Enterprise Value (EV) 1 1,215 1,221 941.1 617.3 514.4 643 619.4 756.1
P/E ratio -15.9 x -15.2 x 11.2 x -3.49 x -2.98 x -3.93 x -6.81 x -9.11 x
Yield - - - - - - - -
Capitalization / Revenue 42.9 x 11 x 2.97 x 8.71 x 8.75 x 5.91 x 3.64 x 2.9 x
EV / Revenue 34.5 x 7.9 x 2 x 5.48 x 5.7 x 4.79 x 2.84 x 2.76 x
EV / EBITDA -8.56 x -11 x 5.55 x -2.47 x -2.05 x -5.34 x 25.4 x 17.8 x
EV / FCF -10.2 x -15.1 x - -2.59 x -2.25 x -4.23 x -25.4 x -687 x
FCF Yield -9.83% -6.63% - -38.6% -44.4% -23.7% -3.94% -0.15%
Price to Book 3.37 x 4.5 x 1.83 x 1.9 x 2.54 x 2.33 x 2.24 x 2.1 x
Nbr of stocks (in thousands) 36,874 37,408 42,769 43,294 43,992 49,043 - -
Reference price 2 40.97 45.36 32.70 22.68 17.95 16.19 16.19 16.19
Announcement Date 20-02-26 21-03-01 22-03-01 23-02-28 24-02-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 35.23 154.6 470.3 112.7 90.24 134.4 218.4 273.7
EBITDA 1 -141.8 -110.8 169.5 -250 -250.8 -120.3 24.43 42.53
EBIT 1 -149 -119.2 160 -262.9 -268.1 -234 -154.3 -148.6
Operating Margin -422.89% -77.14% 34.01% -233.2% -297.12% -174.18% -70.67% -54.28%
Earnings before Tax (EBT) 1 -97.49 -106 141.2 -280.4 -263.6 -208.1 -139.7 -107.5
Net income 1 -94.73 -111.2 127.8 -280.3 -263.5 -210.6 -134.3 -102.5
Net margin -268.88% -71.98% 27.18% -248.68% -291.99% -156.77% -61.47% -37.45%
EPS 2 -2.580 -2.980 2.910 -6.500 -6.020 -4.119 -2.376 -1.777
Free Cash Flow 1 -119.4 -80.93 - -238.2 -228.4 -152.1 -24.4 -1.1
FCF margin -338.96% -52.36% - -211.32% -253.06% -113.21% -11.17% -0.4%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 20-02-26 21-03-01 22-03-01 23-02-28 24-02-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 30.77 398.7 22.22 32.65 26.51 31.34 19.14 19.98 28.91 22.21 23.52 25.19 26.84 42.67 21.39
EBITDA -54.52 316.2 -68.94 -59.89 -67.5 -53.64 -61.98 -68.67 -60.59 - - - - - -
EBIT 1 -57.35 313.6 -71.53 -62.53 -71.04 -57.77 -66.16 -73.11 -64.96 -63.9 -60.37 -60.01 -59.09 -57.26 -55.5
Operating Margin -186.36% 78.66% -321.93% -191.53% -267.97% -184.31% -345.68% -365.96% -224.67% -287.68% -256.64% -238.22% -220.16% -134.2% -259.51%
Earnings before Tax (EBT) 1 -58.4 307.4 -76.76 -68.18 -75.48 -59.98 -66.68 -72.06 -61.87 -63.04 -58.65 -57.69 -55.38 -36.51 -51.29
Net income 1 -58.4 294 -76.72 -68.18 -75.48 -59.94 -66.68 -72.06 -61.87 -62.89 -58.07 -57.22 -55.21 -38.69 -51.29
Net margin -189.79% 73.75% -345.32% -208.82% -284.72% -191.21% -348.4% -360.72% -213.97% -283.12% -246.82% -227.16% -205.72% -90.67% -239.81%
EPS 2 -1.370 6.670 -1.790 -1.580 -1.750 -1.380 -1.530 -1.660 -1.410 -1.430 -1.267 -1.236 -1.183 -0.8597 -1.120
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 21-11-02 22-03-01 22-05-04 22-08-03 22-11-03 23-02-28 23-05-03 23-08-02 23-11-08 24-02-27 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 296 476 457 365 275 151 175 37.9
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -119 -80.9 - -238 -228 -152 -24.4 -1.1
ROE (net income / shareholders' equity) -19.8% -26.9% 22.4% -43.8% -63.7% -35.8% -0.17% 2.66%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 12.20 10.10 17.80 11.90 7.080 6.950 7.220 7.710
Cash Flow per Share 2 - -1.450 4.980 -4.810 -4.990 -2.770 3.760 -
Capex 1 11.7 26.9 84.2 30.7 9.96 9.55 14.3 21.3
Capex / Sales 33.26% 17.38% 17.9% 27.26% 11.04% 7.11% 6.55% 7.78%
Announcement Date 20-02-26 21-03-01 22-03-01 23-02-28 24-02-27 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for REGENXBIO Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.19 USD
Average target price
39.83 USD
Spread / Average Target
+146.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENXBIO INC. Stock REGENXBIO Inc.
-9.81% 794M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RGNX Stock
  4. Financials REGENXBIO Inc.